XAIR - Beyond Air Inc Stock Price, Fair Value and News

$0.49-0.03 (-5.77%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

XAIR Price Action

Last 7 days

2.1%

Last 30 days

36.1%

Last 90 days

16.7%

Trailing 12 Months

-68.8%

XAIR RSI Chart

XAIR Valuation

Market Cap

35.4M

Price/Earnings (Trailing)

-0.64

Price/Sales (Trailing)

15.1

EV/EBITDA

-0.35

Price/Free Cashflow

-0.64

XAIR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

XAIR Fundamentals

XAIR Revenue

Revenue (TTM)

2.3M

Rev. Growth (Yr)

166.62%

Rev. Growth (Qtr)

20.2%

XAIR Earnings

Earnings (TTM)

-54.9M

Earnings Growth (Yr)

23.34%

Earnings Growth (Qtr)

-9.48%

XAIR Profitability

Operating Margin

-97.65%

EBT Margin

-2745.30%

Return on Equity

-187.35%

Return on Assets

-103.53%

Free Cashflow Yield

-155.86%

XAIR Investor Care

Shares Dilution (1Y)

125.78%

Diluted EPS (TTM)

-1.41

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.2M	1.8M	2.3M	0
2023	4.8M	3.9M	3.0M	2.1M
2021	873.1K	0	0	0
2020	1.4M	1.3M	1.1M	1.0M
2019	7.7M	6.1M	4.6M	3.0M
2018	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Beyond Air Inc

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

CEO	Mr. Steven Adam Lisi
WEBSITE	beyondair.net
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	98

Beyond Air Inc Frequently Asked Questions

What is the ticker symbol for Beyond Air Inc? What does XAIR stand for in stocks?

XAIR is the stock ticker symbol of Beyond Air Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Beyond Air Inc (XAIR)?

As of Wed Nov 20 2024, market cap of Beyond Air Inc is 35.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XAIR stock?

You can check XAIR's fair value in chart for subscribers.

Is Beyond Air Inc a good stock to buy?

The fair value guage provides a quick view whether XAIR is over valued or under valued. Whether Beyond Air Inc is cheap or expensive depends on the assumptions which impact Beyond Air Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XAIR.

What is Beyond Air Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, XAIR's PE ratio (Price to Earnings) is -0.64 and Price to Sales (PS) ratio is 15.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XAIR PE ratio will change depending on the future growth rate expectations of investors.